US Stock MarketDetailed Quotes
ANIX Anixa Biosciences
- 2.690
- 0.0000.00%
Close Dec 20 16:00 ET
86.56MMarket Cap-6.90P/E (TTM)
2.690High2.576Low96.13KVolume2.640Open2.690Pre Close251.76KTurnover0.32%Turnover RatioLossP/E (Static)32.18MShares5.13052wk High3.97P/B82.19MFloat Cap2.14552wk Low--Dividend TTM30.55MShs Float8.950Historical High--Div YieldTTM4.23%Amplitude0.056Historical Low2.618Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Anixa Biosciences Stock Forum
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. ...
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• Data continues positive trend as additional patients are enrolled in 3 cohorts
• Vaccine was safe and well tolerated by participants in all 3 cohorts
• Protocol defined immune responses were exhibited in over 70% of patients
• A Phase 2 study evaluating the vaccine in the n...
Anixa Biosciences Inc - to Release Phase 1 Breast Cancer Vaccine Data on Nov 8
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences (NASDAQ: ANIX) has announced its strategic plan for a Phase 2 study of its breast cancer vaccine. The trial will evaluate the vaccine's efficacy in combination with chemotherapy and Keytruda in a neoadjuvant setting. This approach allows for a broader patient range and a potentially faster path to approval. The therapeutic breast cancer market is projected to reach $89.67 bil...
Anixa Biosciences Inc. (NASDAQ: ANIX) recently announced a milestone in its collaborative efforts with Moffitt Cancer Center. The U.S. Food and Drug Administration (FDA) has granted approval for an individual patient Investigational New Drug Application (IND), allowing the administration of a second dose of its CAR-T therapy fo...
No comment yet